PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026Catalysts0 citationsOpen Access

Enhancing the Catalytic Activity of Candida antarctica Lipase B (CALB) for the Synthesis of Moxifloxacin Intermediates by Loop Engineering

View Full Paper
SWSining WeiHenan University of Science and TechnologyMAMahwish AzizNanjing Tech UniversityYZYilin ZhangTaiyuan Heavy Industry (China)

Key Points

  • This study aims to improve the catalytic activity of Candida antarctica lipase B for synthesizing chiral intermediates of moxifloxacin.
  • Employs a structure-guided protein engineering strategy to modify CALB functional domains.
  • Constructs a site-directed saturation mutation library targeting the critical region (143–146).
  • Validates the engineered mutant I189K/L144R/A146K through high-throughput screening and chiral HPLC.
  • The engineered mutant achieves an enhanced kcat/Km of 273.73 min−1·mM−1, about 4.5-fold that of I189K.
  • At 1 M substrate concentration, the mutant reaches 50% conversion in 2.6 hours.
  • Molecular simulations show that L144R and A146K mutations optimize distances between catalytic residues for improved performance.

Abstract

This study addressed the issue of insufficient activity in CALB lipase during the catalytic synthesis of key chiral intermediates for moxifloxacin. A structure-guided protein engineering strategy was employed to systematically modify its functional domains. Through molecular dynamics simulations of CALB-I189K, multiple regions exhibiting high conformational flexibility were preliminarily identified. Subsequently, by integrating 3D structural alignment with active site pocket distance analysis, the functionally most critical region (143–146) was selected. A site-directed saturation mutation library was constructed specifically targeting this region. Building upon the previously reported CALB-I189K, a mutant I189K/L144R/A146K was ultimately obtained through high-throughput screening combined with chiral HPLC validation. This mutant maintains excellent stereoselectivity (E = 206.52) while enhancing catalytic efficiency (kcat/Κm) to 273.73 min−1·mM−1, approximately 4.5-fold that of I189K. At a substrate concentration of 1 M, it achieves 50% conversion within 2.6 h, demonstrating kinetic resolution capabilities approaching industrial standards. Molecular simulation analysis indicates that the L144R and A146K mutations synergistically enhance catalytic performance primarily by optimizing spatial distances between catalytic residues. This study not only provides a high-performance catalyst for the efficient biosynthesis of moxifloxacin chiral intermediates but also offers new insights for enzyme rational design based on dynamic structural information.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wei et al. (2026) studied this question.

synapsesocial.com/papers/69edad274a46254e215b4cd6https://doi.org/10.3390/catal16050377
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation2007 · 4,155 citations
  2. 2High performance liquid chromatography assay with ultraviolet detection for moxifloxacin: Validation and application to a pharmacokinetic study in Chinese volunteers2010 · 39 citations
  3. 3A simple method to determine the enantiomeric ratio in enantioselective biocatalysis1993 · 228 citations
  4. 4Highly efficient racemisation of a key intermediate of the antibiotic moxifloxacin2011 · 21 citations
  5. 5Protein engineering of microbial enzymes2010 · 132 citations